Tuesday November 24 2009 | Biotechnology feed | All feeds

BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

MorphoSys AG

MorphoSys AG, located in Martinsried/Munich, is one of the world's leading biotechnology companies focusing on fully human antibodies. With its unique technologies, MorphoSys is developing the next generation of antibodies, which can be used to treat diseases and for research and diagnostics purposes. Numerous partnerships have already been entered into with well-known companies from the pharmaceutical and biotechnology sectors, such as Bayer, Boehringer Ingelheim, Centocor/Johnson & Johnson, Daiichi Sankyo, Novartis, Pfizer, Roche and Schering.The Company, founded in 1992, possesses the unique HuCAL technology (the Human Combinatorial Antibody Library). This library comprises more than ten billion different, fully human antibodies. HuCAL is a very powerful technology, which allows rapid and automated production of high-affinity antibodies. The most important feature of the library is its capability of optimizing fully human antibodies to meet predefined specifications.
Presently, MorphoSys prosecutes its business in two operating segments. One segment, the Therapeutic Antibodies unit, develops drug candidates for commercial partners as well as MorphoSys's own proprietary product pipeline. In this regard, the Company has been successful in establishing a number of partnerships with renowned biotechnology and pharmaceutical companies and also generated several proprietary therapeutic antibody candidates for out-licensing to partners. MorphoSys's second operating segment, the Research Antibodies unit, delivers high-quality antibodies to the research market, under the brand AbD – Serotec. The recent acquisitions of Serotec and Biogenesis, which bring strong catalog and industrial antibody production business, have signficantly strengthened and broadened MorphoSys's position in the research antibody market. The resulting combined activities of MorphoSys’s AbD unit serve all segments of the research and diagnostics markets.


Contact Details:
Lena-Christ-Strasse 48
Martinsried
Planegg
82152
Germany
Tel:49 (0)89 / 899 27-0
Fax:49 (0)89 / 899 27-222
Email:investors@morphosys.com
WWW:

www.ab-direct.com/




Recent Publications by MorphoSys AG:

The Role of Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 in the p38/TNF-alpha Pathway of Systemic and Cutaneous Inflammation.
Mitogen-activated protein kinase-activated protein kinase 2 (MK2) is a...
7th August, 2009
MorphoSys AG, Martinsried, Germany. J Invest Dermatol. 2009 Aug 6.
DOI Direct Link
In vitro affinity maturation of human GM-CSF antibodies by targeted CDR-diversification.
The mammalian immune system applies somatic hypermutation to select for...
9th April, 2009
MorphoSys AG, Lena-Christ-Str. 48, Martinsried 82152, Germany. Mol Immunol. 2008 Nov;46(1):135-44. Epub 2008 Aug 21.
DOI Direct Link
Recombinant monoclonal antibodies.
Recombinant antibody technology is a rapidly evolving field that enables...
12th August, 2008
Department of Research, MorphoSys AG, Martinsried, Germany. Methods Mol Biol. 2007;378:14-31.
The human combinatorial antibody library HuCAL GOLD combines diversification of all six CDRs according to the natural immune system with a novel display method for efficient selection of high-affinity antibodies.
This article describes the generation of the Human Combinatorial Antibody...
20th March, 2008
MorphoSys AG, Lena-Christ-Strasse 48, 82152 Martinsried, Germany. J Mol Biol. 2008 Feb 29;376(4):1182-200. Epub 2007 Dec 15.
DOI Direct Link
Generation and optimization of human antagonistic antibodies against TIMP-1 as potential therapeutic agents in fibrotic diseases.
Impaired matrix metalloproteinase 1 (MMP-1) function, as result of the...
22nd August, 2007
MorphoSys AG, Lena-Christ-Str. 48, 82152 Martinsried/Planegg, Germany. Hum Antibodies. 2006;15(4):115-24.

View more MorphoSys AG research publications.

Press Releases on MorphoSys AG:

BioPortfolio Logo
DSM Biologics and MorphoSys AG to Manufacture Fully Human Antibody 12th August, 2008 DSM Biologics
PARSIPPANY, N.J., Aug. 12 /PRNewswire/ -- DSM Biologics and MorphoSys AG (Frankfurt Stock Exchange: MOR; Prime Standard Segment, TecDAX) today announced the signing of a Biopharmaceutical
BIO Deutschland: Independent Biotechnology Industry Organisation Founded 1st October, 2004 Bio Deutschland
BIO Deutschland: Independent Biotechnology Industry Organisation Founded 29 October 2004 Berlin - Leading companies from the German biotechnology sector have established a new and independent
MorphoSys Reports third quarter 2004 results. Company expects to obtain 1st September, 2004 Morphosys
MorphoSys Reports third quarter 2004 results. Company expects to obtain profitablity by 2005 Martinsried/Munich, October 28, 2004 MorphoSys AG (Frankfurt Stock Exchange: MOR; Prime
MorphoSys Generated Antibody Approved to Enter Clinical Trials 1st January, 1970 Morphosys
MorphoSys Generated Antibody Approved to Enter Clinical Trials Martinsried/Munich, December 09, 2004 - MorphoSys AG (Frankfurt Stock Exchange: MOR; Prime Standard Segment; TecDAX)
MorphoSys Antibodies by Design, ProQinase and Natural and Medical 1st January, 1970 Morphosys
MorphoSys Antibodies by Design, ProQinase and Natural and Medical Sciences Institute (NMI) receive BMBF-promotion for Kinome-project ASK-chip shall enable targeted functional analysis of

BioNews Results for MorphoSys AG:

MorphoSys gets regulatory approval to begin phase 1b/2a trial for MOR103 programme
PharmaBiz:  Nov 11 2009 1:22PM Matching: morphosys ag
MorphoSys Receives Regulatory Approval to Start Phase 1b/2a Clinical Trial for MOR103 Program
Bionity.com:  Nov 10 2009 11:05PM Matching: morphosys ag
MorphoSys Receives Regulatory Approval to Start Phase 1b/2a Clinical Trial for MOR103 Program
Pharma Live:  Nov 9 2009 4:42PM Matching: morphosys ag
MorphoSys Receives Regulatory Approval to Start Phase 1b/2a Clinical Trial for MOR103 Program
Genetic Engineering News:  Nov 9 2009 7:38AM Matching: morphosys ag
MorphoSys Receives Regulatory Approval to Start Phase 1b/2a Clinical Trial for MOR103 Program
Individual.com:  Nov 9 2009 6:46AM Matching: morphosys ag
Promote your company here: BioNewsCast - Press Release Distribution

View more MorphoSys AG news.

MorphoSys AG Patents:

US Patent No.Title
7521047 Human polypeptides causing or leading to the killing of cells including lymphoid tumor cells
6300064 Protein/(poly)peptide libraries
6653068 Generation of specific binding partners binding to (poly)peptides encoded by genomic DNA fragments or ESTs
6667150 Method and phage for the identification of nucleic acid sequences encoding members of a multimeric (poly) peptide complex
6692935 Targeted hetero-association of recombinant proteins to multi-functional complexes

View more MorphoSys AG patents.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 433 times since April 2007, the link to the organisation's website has been followed 95 times

Recent Search Terms used to find this page: morphosys GERMANY EMAIL | morphosys germany | MorphoSys leading company press | morphosys ag martinsried | morpho-sys | morpho-sys | morphosys stock deutschland | antibody production planegg job | MorphoSys AG Reports Six Months 2009 Results | .

Search for more companies in Martinsried

Search for more companies in Planegg



This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for MorphoSys AG

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.